IP Library Granted Patent US 8,445,654
Granted Patent B2
US 8,445,654 · App. 13/280,148 · Granted May 21, 2013

Antibiotic macrocycle compounds and methods of manufacture and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,654
App. No.
13/280,148
Granted
May 21, 2013
Kind
B2
Abstract

The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile ( C. difficile ) and Clostridium perfringens ( C. perfringens ).

Claims (9)

1. An isolated compound of Formula II

in free form or in the form of its pharmaceutically acceptable salt.

2. The isolated compound of claim 1 , wherein the compound of Formula II is greater than 80% by weight stereomerically pure.

3. The isolated compound of claim 1 , wherein the compound of Formula II is an alkaline metal or tertiary alkyl ammonium salt.

4. The isolated compound of claim 1 , wherein the compound of Formula II is a Na + , K + , Mg 2+ , Ca 2+ , Zn 2+ salt.

5. The isolated compound of claim 1 , wherein the compound of Formula II is greater than 90% by weight stereomerically pure.

6. The isolated compound of claim 1 , wherein the compound of Formula II is greater than 95% by weight stereomerically pure.

7. The isolated compound of claim 1 , wherein the compound of Formula II is greater than 97% by weight stereomerically pure.

8. The isolated compound of claim 1 , wherein the compound of Formula II is substantially free of other diastereomers of the compound.

Assignments (5)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 14, 2015
From: OPTIMER PHARMACEUTICALS LLC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036328/0122 →
CHANGE OF NAME Recorded Aug 12, 2015
From: OPTIMER PHARMACEUTICALS, INC.
To: OPTIMER PHARMACEUTICALS LLC
Reel/Frame 036333/0793 →
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: TRIUS THERAPEUTICS, INC.; OPTIMER PHARMACEUTICALS, INC.
Reel/Frame 036178/0175 →
SECURITY AGREEMENT Recorded Nov 13, 2013
From: OPTIMER PHARMACEUTICALS, INC.; TRIUS THERAPEUTICS INC.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 031628/0850 →